TABLE 3.
Human FcRn binding to Y31-YTE motavizumab (432–437 sequence: ERFHRQ) variants with amino acid substitutions at the 434-position
| Amino acid at 434 position | pH 6.0 KDa | pH 7.4 KDa |
|---|---|---|
| nm | nm | |
| Phe (Y31-YTE) | 84 | 1160 |
| Tyr | 48 | 1350 |
| Trp | 41 | 2120 |
| Leu | 6050 | >10,000 |
| Ile | 2750 | >10,000 |
| Val | 1390 | >10,000 |
| Met | 1740 | >10,000 |
| Ala | 390 | 2640 |
| Ser | 328 | 4540 |
| Thr | 858 | >10,000 |
| Gln | 369 | 4920 |
| Asn | 673 | 6920 |
| Asp | 4850 | >10,000 |
| Glu | >10,000 | >10,000 |
| His | 67 | 1440 |
| Lys | 1900 | >10,000 |
| Arg | 1860 | >10,000 |
| Gly | 200 | 2290 |
| Cys | 1680 | >10,000 |
| Prob |
a Steady-state affinity measurements carried out by ProteOn as described under Experimental Procedures. Values in italics were determined via kinetic model (Langmuir with mass transfer).
b Y31-YTE 434P had no expression.